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Down syndrome (DS; trisomy 21) is the most common survivable disorder due to aneuploidy. Individ-
uals with DS may experience multiple comorbid health problems including congenital heart defects,
endocrine abnormalities, skin and dental problems, seizure disorders, leukemia, dementia, and obesity.
These associated conditions may necessitate pharmacotherapeutic management with various drugs.
The complex pathobiology of DS may alter drug disposition and drug response in some individuals.
For example, reports have documented increased rates of adverse drug reactions in patients with DS
treated for leukemia and dementia. Intellectual disability resulting from DS may impact adherence to
medication regimens. In this review, we highlight literature focused on pharmacotherapy for individu-
als with DS. We discuss reports of altered drug disposition or response in patients with DS and
explore social factors that may impact medication adherence in the DS setting. Enhanced monitoring
during drug therapy in individuals with DS is justified based on reports of altered drug disposition,
drug response, and other characteristics present in this population.
KEY WORDS Down syndrome, trisomy 21, pharmacotherapeutics, medication adherence, gene dosage
effect, seizure disorder, leukemia, adverse drug reactions.
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Down syndrome (DS), also known as trisomy
21, is the most common survivable chromosomal
disorder due to aneuploidy.1 The incidence of
DS in the United States is ~1 per 700 live births,
and the worldwide incidence is ~1 per 1000 live
births.1 DS is caused by the presence of an addi-
tional whole or partial copy of chromosome 21
in affected individuals that results in genome-
wide imbalances with a range of phenotypic con-
sequences.2 Individuals with DS often exhibit
associated disorders that contribute to elevated
health care needs and financial costs.3 In spite of
the high incidence of multiple adverse health
conditions, the life expectancy of individuals
with DS has increased to ~60 years of age.4 Indi-
viduals with DS will likely have increased health
care needs as they age.5
The complex pathobiology of DS results in
physical deficits and biochemical changes that
can lead to multiple comorbid conditions. Gas-
trointestinal malformations such as duodenal
stenosis and Hirschsprung disease are associated
with DS.6 DS can impact immune responses,
resulting in individuals being more susceptible to
certain infections (e.g., upper respiratory tract
infections).7 Celiac disease and other food intol-
erances are also more common in individuals
with DS.8, 9 Congenital heart defects are common
in those with DS, whereas the incidence of coro-
nary artery disease (CAD) is lower than in
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subjects without DS.10 One study found that
9.9% of persons with DS older than 40 years died
as a result of CAD.11 A lower level of homocys-
teine in individuals with DS is thought to con-
tribute to the reduced incidence of CAD;
however, this has yet to be confirmed.12 The fre-
quency of congenital hypothyroidism is 28 times
higher in individuals with DS in comparison with
those without DS.13 Multiple skin conditions are
also associated with DS and can lead to recurrent
skin and soft tissue infections.14 DS is a leading
cause of intellectual disability.15 Neurologic con-
ditions such as seizure disorders and early-onset
dementia are prevalent in the DS population.
Children with DS are at an increased risk for
hematologic disorders such as acute myeloid leu-
kemia, acute lymphoblastic leukemia, and ane-
mia.16 Obesity, dental problems, and apnea are
also associated with DS.17
Although some physical deficits in DS may be
corrected with surgery, medications are often
used to manage various comorbid health condi-
tions in individuals with DS. This results in high
rates of medication use by those with DS.18
Unfortunately, there is often a lack of prospec-
tive research to make evidence-based recommen-
dations for all DS-associated conditions and
anomalies. Thus the treatment of comorbid con-
ditions associated with DS can be a daunting task
for health care providers and often requires mul-
tiple approaches. This concise review highlights
the literature that focuses on pharmacotherapy
for individuals with DS, indicates incidences of
altered drug disposition or response, and justifies
the need for further investigation of drug therapy
in individuals with DS. This information may be
relevant for health care professionals who man-
age patients with DS.
Literature Review
Published reports concerning medication use,
adherence, disposition, and effect in subjects
with DS were considered for this review. The
PubMed and Ovid databases were used to search
and identify the reports. These keywords were
used: Down syndrome, trisomy 21, pharmacother-
apy, adverse drug reaction, drug treatment, phar-
macokinetics, pharmacodynamics, and drug
metabolism. The search was performed from
March 2016 through July 2016 and yielded pri-
mary research articles as well as other relevant
reviews on related topics. The publication dates
of reports used in this review spanned from
1981 to 2016.
Alterations in Drug Disposition and Drug
Response
Dementia and Psychiatric Disorders
Individuals with DS have a greater risk of
developing Alzheimer’s-like dementia earlier in
life compared with individuals without DS.19
Rivastigmine, galantamine, memantine, and done-
pezil have been used to treat Down syndrome–
associated dementia (DSAD).20 Donepezil has
shown significant therapeutic efficacy in multiple
reports. One small study showed improvement in
dementia scores in subjects treated with donepe-
zil during the 3- to 5-month time period
(p=0.03). Subjects were treated with initial doses
of donepezil 5 mg/day for 50 days, followed by
10 mg/day for 60 days.21 Other studies did not
show significant improvement in subjects with
DSAD who were treated with donepezil.22 Ele-
vated frequencies of adverse effects from donepe-
zil have been reported in subjects with DSAD.23
For example, in two separate reports, a total of
six individuals with DSAD developed gastroin-
testinal disturbances, altered mental status, or uri-
nary incontinence following treatment with
donepezil of varying duration (weeks to
months).24, 25 A small group of 14 healthy sub-
jects with DS did show higher donepezil plasma
concentrations than a comparator group of 6
healthy subjects without DS.25 In this study, the
mean donepezil plasma concentration (while
receiving donepezil 3–5 mg/day for 5 days) in
subjects with DS was 17.9 and 28.2 ng/ml at
doses of 3 mg/day and 5 mg/day, respectively,
versus a mean plasma concentration of 7.8 and
17.7 ng/ml in the group of subjects without DS
taking similar doses, respectively (p<0.001). The
authors speculated that altered pharmacokinetics
of donepezil could play a role in the increased
incidence of adverse effects in subjects with
DSAD and suggested that donepezil doses as low
as 3 mg/day should be adequate for most patients
with DSAD. It has been postulated that initiating
treatment with donepezil at a lower dose and then
titrating this dose, if necessary, may reduce the
frequency of adverse effects in individuals with
DSAD.20 Rivastigmine, a cholinergic agent used
for the treatment of mild to moderate dementia,
has also been studied in subjects with DSAD. In
one double-blind placebo-controlled trial in 22
children and adolescents with DS, rivastigmine
treatment did not improve cognition, language,
or overall function.26 It was noted that subjects
with DSAD tolerated rivastigmine therapy well.
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Patients with DS can have high utilization
rates of antidepressant and antipsychotic medica-
tions.18 These medications are given to some
patients with DS and dementia to manage sym-
ptoms as well as other psychological disorders.27
One case series explored the efficacy of admi-
nistering antidepressants such as sertraline,
fluoxetine, and citalopram to manage obsessive-
compulsive disorder in four individuals with DS.
It was reported to be an effective strategy.28 One
retrospective chart review suggested that the use
of antidepressants (98% serotonin and serotonin-
norepinephrine reuptake inhibitors) resulted in a
1.31-year delay in the onset of dementia
(p=0.038) in individuals with DS.29 The authors
indicated the need for prospective studies to con-
firm their findings.
Seizure Disorders
Seizure disorders are associated with DS from
childhood to adulthood.30 Individuals with DS
and seizure disorders are treated with traditional
anticonvulsants. Therapy with multiple anticon-
vulsants such as carbamazepine, phenytoin, and
valproic acid may be necessary for seizure con-
trol. It has been hypothesized that anticonvul-
sant polypharmacy may contribute to sudden
unexpected death in some individuals with DS
and epilepsy.31 Elevated homocysteine plasma
levels and decreased folic acid plasma levels
have been reported in individuals with DS fol-
lowing therapy with valproic acid.32 Hyperho-
mocysteinemia is a risk factor for cardiovascular
disease, and supplementation with folic acid
may be necessary for patients with DS who are
receiving therapy with valproic acid.32 Reports
of drug-induced seizures in those with DS are
rare. One case report described a single patient
with DS who developed seizures after treatment
with the antihelminthic thiabendazole.33 The
author attributed the seizure to the person hav-
ing DS; however, no follow-up study corrobo-
rated this observation.
Anticonvulsants such as carbamazepine and
phenytoin, although necessary for seizure con-
trol in some patients, have the potential to fur-
ther exacerbate other comorbid conditions and
effects of DS. The potential exists for these
agents and others to further reduce cognitive
function in individuals with DS.34 Carba-
mazepine also has the potential to exacerbate
hypothyroidism in individuals with DS, and
affected individuals may require increased doses
of levothyroxine.35 The potential for adverse
effects of pharmacotherapy with anticonvulsants
in individuals with DS may necessitate gradual
titration to effect and enhanced monitoring.36
Respiratory Disorders
Respiratory disorders are common in people
with DS. Impaired immune system function
combined with respiratory tract defects make
respiratory diseases a serious concern in individ-
uals with DS.37 Antibiotic therapy or inhaled
bronchodilators may be needed to treat some
respiratory problems related to DS.38 A case ser-
ies showed that the pharmacokinetics of the
bronchodilator theophylline was altered in six
infants with DS and apnea.39 Specifically, it was
reported that infants with DS exhibited reduced
theophylline clearance. The observed mean
clearance for the group with DS was 0.051 
0.035 L/kg/hour, whereas the expected range of
clearance values for infants of similar ages was
0.089–0.102 L/kg/hour. In this study, no statisti-
cal comparisons were reported, and the authors
noted that the use of concurrent medications
could have impacted the observations. The
authors speculated that the abnormal clearance
of theophylline in the infants with DS could be
related to altered levels of growth hormone that
would in turn impact the expression of cyto-
chrome P450 (CYP) drug-metabolizing enzymes.
It should be noted that this was a retrospective
case series. No prospective studies have yet sub-
stantiated these findings.
Hematologic Malignancies
Children with DS have an elevated risk of
developing certain hematologic malignancies,
such as acute myeloid leukemia.40 These patients
are generally treated with cytotoxic chemother-
apy regimens that are often highly efficacious.
Unfortunately, children with DS often display
increased adverse effects from the chemother-
apy.16 Potential contributing factors for this may
include an underlying pro-oxidative state. Altered
disposition of specific cytotoxic agents may play
a role as well. Pediatric patients with DS dis-
played higher intracellular thioguanine metabo-
lite concentrations when compared with those
without DS.41 Elevated 42-hour methotrexate
plasma concentrations were observed in subjects
with DS.41 Most studies that considered the phar-
macokinetics of cytotoxic chemotherapeutic
agents in patients with DS postulated that altered
cellular environments in the DS setting, rather
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than pharmacokinetics, drive the differential
response to chemotherapy agents.41 Few large
prospective studies have investigated the impact
of altered chemotherapy dosing in patients with
DS; however, the reports that do exist often rec-
ommend treating hematologic malignancies with
reduced doses of select cytotoxic chemotherapeu-
tics, combined with close monitoring for toxic-
ity.16 Pediatric patients with DS and leukemia
who received prednisone with L-asparaginase dis-
played hyperglycemia at a higher rate compared
with patients without DS.42 The authors sug-
gested that this phenomenon was likely due to
baseline insulin resistance in patients with DS.
Other Potential Pharmacotherapeutic
Considerations
Besides biochemical alterations, DS can result
in numerous physical anomalies that may impact
pharmacotherapy. Individuals with DS and con-
genital hypothyroidism generally require supple-
mentation with levothyroxine. One retrospective
study that considered children with DS reported
that therapy with low-dose levothyroxine
(2.6 lg/kg/day) was adequate for hypothy-
roidism.13 The authors also recommended early
screening for thyroid dysgenesis in children with
DS and lifelong treatment with levothyroxine in
those who are positive for the condition. The
presence of uncorrected congenital heart defects
necessitates antibiotic prophylaxis prior to many
dental procedures.43 Cardiac deficits may play a
role in sudden unexpected death in individuals
with DS and epilepsy who are taking multiple
anticonvulsants, although this has not been con-
firmed in prospective studies.31 People with DS
may require surgery to correct cardiac defects.
The administration of anesthetic agents to indi-
viduals with DS prior to surgery requires special
considerations. This is due to their unique air-
ways and musculoskeletal and other systemic
characteristics that may be present in subjects
with DS.44 In general, the requirements of nar-
cotic-based therapy for the control of postopera-
tive pain in patients with DS are similar to those
for patients without DS. Retrospective studies
have shown that therapeutic responses to opioid
and nonopioid pain relievers after cardiac sur-
gery were similar in both pediatric patients with
and without DS.45
Altered drug absorption in individuals with DS
has yet to be thoroughly explored. Some comor-
bid conditions associated with DS and their
respective treatments have been shown to impact
drug absorption and should be considered when
assessing pharmacotherapeutic options in this
patient population. Gastrointestinal malforma-
tions are more common in individuals with DS
and can require surgery to correct.46 Gastroin-
testinal surgery and disease have the potential to
alter drug and nutrient absorption by altering pH,
gastric emptying, and overall intestinal surface
area.47 Celiac disease present in those with DS
may impact drug absorption; however, this has
yet to be confirmed with large prospective stud-
ies.48 The malabsorption of folic acid, iron, and
cyanocobalamin associated with celiac disease
may be a potentiating factor for anemia in
some individuals with DS.49
Social Considerations
DS is the leading cause of intellectual disabil-
ity.1 The degree of this impairment, as well as
socioeconomic status, can vary among individu-
als and influence the daily needs and living
arrangements of those with DS. These living
arrangements (e.g., group home, semi-indepen-
dent living, or family home) can potentially
impact adherence to medications and vaccina-
tion guidelines. It has been reported that indi-
viduals with intellectual disabilities (including
DS) living in a family home displayed higher
rates of nonadherence to medication regimens
compared with those in group homes.50 Semi-
independent living arrangements were also
negative predictors of adherence in those with
intellectual disabilities compared with those in a
group home setting.50 Guardians of children
with DS may also influence therapy. One study
reported that guardians of children with intellec-
tual disabilities were more likely to refuse to
vaccinate them.51
Individuals with DS have been shown to be at
a higher risk for being socioeconomically disad-
vantaged, which may also impact adherence to
treatment and vaccination guidelines.52 Poor
adherence to guidelines may compromise the
management of certain diseases in some individ-
uals with DS. A study on children with DS
found low levels of adherence to the American
Academy of Pediatrics guidelines for thyroid
screening.53 It has been shown that subjects with
developmental disabilities (including those with
DS) from different racial or ethnic groups
showed disparities in terms of adherence to
antidiabetic medications.54 Adherence to medi-
cation regimens is critical for treatment success.
Poor medication adherence can contribute to
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treatment failure, disease progression, and
increased health care costs.55 Few pros-
pective studies have considered DS status as a
factor potentially associated with medication
adherence.
Discussion
Individuals with DS have distinctive biochemi-
cal and physical characteristics that can impact
pharmacotherapy. To provide optimal care, it is
important to recognize that persons with DS
may respond differently to specific drug
therapies. Based on the evidence available, the
differential drug responses observed in DS
appear to be largely driven by pharmacodynamic
factors. Some drug-metabolizing enzymes, such
as carbonyl reductase 1, are encoded in
chromosome 21 and do exhibit differential
expression in some tissues in individuals with
DS.56 Little evidence is available on differential
CYP enzyme expression in persons with DS,
and, as of yet, no evidence has linked altered
drug disposition to the expression of CYP
enzymes in individuals with DS. One report did
indicate that single nucleotide polymorphisms in
the CYP17 and CYP19 genes in those with DS
may impact the bioavailability of endogenous
estrogen, but therapeutic recommendations were
not discussed.57
Although evidence from well-powered studies
is scarce, some reports suggest that those with DS
can exhibit altered drug response in certain cir-
cumstances.16 Pediatric patients with DS and
hematologic malignancies exemplify this notion;
however, a large gap of knowledge remains.16 As
individuals with DS live longer, they will likely
encounter more age-related medical conditions.
Medication utilization patterns, living conditions,
and the status of caregivers are likely to shift with
increasing age to include agents not well studied
in those with DS, which may pose a risk to this
group. Currently, there is scant research that con-
siders pharmacotherapy in individuals with DS as
well as the many chronic conditions they com-
monly face.58 The level of information derived
from studies investigating the efficacy and adverse
effects of pharmacotherapy in those with DS is,
for the most part, inadequate.
Multiple obstacles must be overcome to
research the medication effects in individuals
with DS. Preclinical studies can be encumbered
by subject availability.59 Many of the clinical
studies that explored pharmacotherapy in sub-
jects with DS were small, and others only
included results from a subgroup of subjects
with DS. Clinical studies to ascertain the efficacy
of psychotropic medications in subjects with DS
may be challenging given the language and com-
munication characteristics of individuals with
DS.60 The intellectual disability associated with
DS, as well as inadequacies in living arrange-
ments, may be predisposing factors for poor
medication adherence. The reports on pharma-
cotherapy and individuals with DS suggest that
monitoring is essential in this population, espe-
cially when considering that most medications
have not been studied in relatively large groups
of those with DS.
Conclusion
DS is associated with numerous health prob-
lems and high health care costs. Persons with
DS display high medication utilization; however,
few medications are studied in this at-risk popu-
lation. Social conditions can impact medication
utilization, but they remain largely uninvesti-
gated in DS. Based on the information available,
individuals with DS may require more intense
monitoring for adverse effects, adherence, and
treatment efficacy when being managed with
medications. A more complete delineation of the
factors that impact pharmacotherapy in the DS
setting would contribute to the improvement of
the clinical care of persons with DS.
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